Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company distributes and sells plant-based pharmaceutical products.
| Line item | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|
| 305 | 1,387 | 2,659 | +195.4% | |
| Total Non-Current Assets | 179 | 142 | 95 | -27.2% |
| TOTAL ASSETS | 483 | 1,529 | 2,754 | +138.7% |
| 18 | 21 | 14 | -11.6% | |
| Total Non-Current Liabilities | 0 | 4 | 0 | |
| TOTAL LIABILITIES | 18 | 25 | 14 | -11.6% |
| 465 | 1,504 | 2,739 | +142.6% | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | |
| Debt analysis | ||||
| Total Debt | 0 | 0 | 0 | |
| Cash & Equivalents | 135 | 793 | 2,265 | +309.9% |
| Net Debt | 135 | 793 | 2,265 | +309.9% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →